TABLE 1.
Baseline characteristics of the study population
| Characteristic | Cohort (FTC q.d. dose)
|
All patients (n = 49) | ||||
|---|---|---|---|---|---|---|
| 25 mg (n = 11) | 50 mg (n = 8) | 100 mg (n = 11) | 200 mg (n = 9) | 300 mg (n = 10) | ||
| Sex (no. [%] of patients) | ||||||
| Male | 8 (73) | 5 (63) | 10 (91) | 6 (67) | 9 (90) | 38 (78) |
| Female | 3 (27) | 3 (38) | 1 (9) | 3 (33) | 1 (10) | 11 (22) |
| Ethnic origin (no. [%] of patients) | ||||||
| Caucasian | 2 (18) | 1 (9) | 1 (10) | 4 (8) | ||
| Black | 1 (9) | 1 (2) | ||||
| Asian | 8 (73) | 8 (100) | 10 (91) | 8 (89) | 9 (90) | 43 (88) |
| Hispanic | 1 (11) | 1 (2) | ||||
| Age (yr) | ||||||
| Mean (SD) | 34 (11.0) | 31 (7.9) | 37 (9.8) | 30 (8.2) | 36 (7.8) | 34 (9.2) |
| Median | 34 | 30 | 34 | 31 | 34 | 32 |
| Minimum-maximum | 19-52 | 20-47 | 26-55 | 19-45 | 25-51 | 19-55 |
| No. [%] of patients who were HBeAg positive | 7 (64) | 6 (75) | 11 (100) | 9 (100) | 8 (80) | 41 (84) |
| Mean (SD) ALT level (U/liter) | 80 (43) | 101 (45) | 83 (66) | 107 (78) | 114 (122) | 96 (75) |
| Baseline log10 HBV DNA level (no. of copies/ml)a | ||||||
| Median | 8.6 | 7.4 | 7.06 | 8.5 | 7.5 | 7.9 |
| Minimum-maximum | 6.2-9.3 | 7.3-9.1 | 5.8-9.3 | 4.8-10.4 | 6.4-8.7 | 4.8-10.4 |
| No. (%) of evaluable patients | 7 (64) | 8 (100) | 11 (100) | 9 (100) | 10 (100) | 45 (92) |
a
Log10 HBV DNA levels were determined by the Digene assay.